ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine ...

Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected

Related Keywords

United States ,Richard Lowenthal ,Laura Oneill ,Justin Chakma ,Pharmaceuticals Inc ,Nasdaq ,Advisory Committee ,Drug Administration ,Exchange Commission ,New Drug Application ,Complete Response Letter ,Typei Allergic Reactions ,Private Securities Litigation Reform Act ,Annual Report ,Region ,